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Peptides have been studied for over 100 years, but for most of this time the focus was on a
speciﬁc peptide or peptides, and not on the general peptidome of a biological sample. In the
1990s, mass spectrometry techniques were developed for the analysis of proteins, usually
after digestion into peptides. The ﬁeld of peptidomics started soon after proteomics and has
grown to over 600 publications that use the word “peptidomic” or “peptidomics”. Although
peptidomics is related to proteomics, there are fundamental differences. In this review, we
discuss these differences along with the history of the ﬁeld of peptidomics.
©  2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). This is an open access article under the CC BY licenseeptidome
eptide research
eptide hormones
europeptides
iomarker discovery
(http://creativecommons.org/licenses/by/3.0/).
abundant peptides present in a biological sample, which was.  Peptide  research  prior  to  peptidomics
.1.  Early  discovery  of  peptide  hormones
ioactive peptides have been studied for over 100 years, ever
ince Bayliss and Starling found in 1902 that a substance
ecreted by the intestine stimulated the pancreas to secrete
igestive enzymes [1]. This substance was named secretin and
he class of signaling molecules carried by the bloodstream
as  named hormones. Once secretin was puriﬁed and foundo be a peptide, its amino acid sequence was determined.
any  other peptide hormones were discovered using a sim-
lar approach in which a bioactive substance was puriﬁed to
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212-9685/© 2014 The Authors. Published by Elsevier B.V. on behalf of
rticle  under the CC BY license (http://creativecommons.org/licenses/bhomogeneity and sequenced, and several of these discoveries
resulted in Nobel Prizes for the novel groundbreaking scien-
tiﬁc insights how the body communicates internally, locally
between cells and especially via the blood stream between
distant cells and entire organ systems. Similar methods were
used to discover peptide neurotransmitters and peptidergic
neuromodulators, collectively termed neuropeptides. While
these studies involved the discovery of peptides, they were
not designated as peptidomics because they followed a single
bioactive moiety and did not attempt to characterize all of thehulz-knappe@protagen.com (P. Schulz-Knappe),
far too complex for the tools available prior to the 21st century.
Despite the limited tools, several researchers character-
ized peptides present in biological samples without primarily
 European Proteomics Association (EuPA). This is an open access
y/3.0/).
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focusing on biological activity; such “peptide-ﬁrst” approaches
are a hallmark of peptidomics studies. In the early 1980s, Mutt,
Tatemoto, and colleagues puriﬁed peptides from pig intes-
tine. They replaced bioassays by screening for the presence
of a C-terminal amide group, recognizing at that time that C-
terminal amidation is a common feature of peptide hormones.
Using this approach, Mutt and Tatemoto identiﬁed a handful
of peptides that were subsequently found to be neuropeptides
and/or peptide hormones, such as neuropeptide Y, peptide YY,
galanin, and others [2–4]. A decade later, Sigafoos, Viveros,
and colleagues puriﬁed peptides from chromafﬁn granules,
the peptide-rich secretory vesicles of the adrenal medulla [5].
In addition to ﬁnding several novel forms of chromogranins
A and B, they found four novel peptides with no homology to
any known peptides. A search of these peptides in the current
databases show that one corresponds to the C-terminal region
of neuroendocrine secretory protein 55, another corresponds
to the N-terminal region of prohormone convertase 2, and the
other two peptides correspond to proSAAS-derived peptides
named KEP and little SAAS.
Being inspired by their work, and also in close collabora-
tion with the Swedish group, the Heidelberg-based group of
Forssmann isolated peptides of the atrial natriuretic peptide
family from porcine, bovine and equine heart tissue [6]. Driven
by the observation that tissue extraction can lead to biologi-
cally inactive pre-forms of peptide hormones (prohormones)
Forssmann subsequently attempted to systematically address
circulating human peptides from blood in a quest to compre-
hensively discover circulating peptide hormones, and also to
identify the circulating (processed) forms of already known
peptides. At that time HPLC and signiﬁcantly improved and
diversiﬁed chromatography media became available. Peptides
from 800 L of human urine and later from tens of thousands
of liters of human blood ﬁltrate (obtained from patients with
end-stage renal disease) were extracted and puriﬁed [7]. Using
a systematic sequencing approach on this large-scale human
peptide bank, a new human defensin [8] and a chemokine [9]
were puriﬁed and identiﬁed followed by their biological char-
acterization. The analysis of the puriﬁed products involved
mass spectrometry, but ﬁnally relied still on Edman sequenc-
ing for identiﬁcation. Mass spectrometry was already used to
study peptides in the 1990s, but due to limitations in the tech-
niques, the studies were primarily aimed at detecting known
neuropeptides or their degradation fragments [10–12].
1.2.  Isolation  of  neuropeptide  processing-intermediates
Early applications using mass spectrometry to detect peptides
especially from body ﬂuids but also from tissue extracts reg-
ularly reported thousands of peptides to be present in the
samples. Upon closer inspection, the vast majority of these
peptides were protein degradation fragments [13–15] leading
to an uncertainty about the scientiﬁc value of this type of “pep-
tide mapping” excursions. One solution to this problem was to
purify biologically meaningful peptides by enriching for neu-
ropeptide processing intermediates using an afﬁnity column
that bound these intermediates and not the majority of pro-
tein degradation fragments. Most neuropeptides and peptide
hormones are produced from precursor proteins by endopep-
tidase cleavage at sites containing multiple Lys and/or Arg 3 ( 2 0 1 4 ) 171–182
residues followed by exopeptidase removal of these amino
acids from the C-terminus of the processing intermediates.
The enzyme primarily responsible for the second step is car-
boxypeptidase E, which was identiﬁed in the early 1980s
[16,17]. Carboxypeptidase E is mutated in the fat mouse, lead-
ing to a dramatic increase in peptides containing C-terminal
Lys and/or Arg residues [18,19]. Extracts from brains of fat mice
were puriﬁed on an anhydrotrypsin resin to bind peptides
containing C-terminal basic residues, eluted, and analyzed
by liquid chromatography–mass spectrometry (LC–MS). This
resulted in the identiﬁcation of many  known neuropeptides
as well as several novel peptides from a precursor named
proSAAS [20,21]. As with the discovery of neuropeptide Y by
Mutt and Tatemoto, the ﬁnding of novel peptides in mouse
brain did not provide clues as to the function, and only after
extensive additional research has it been determined that
some of the proSAAS-derived peptides play a role in feed-
ing/body weight regulation and reward  pathways [22–25].
2.  Technological  origin  and  developments
2.1.  Deﬁnition  of  peptidomics  and  comparison  to
proteomics
While some of the above studies could be considered
peptidomics, the term was coined at a scientiﬁc meet-
ing organized by Micromass in the late nineties (Shrigley
Hall, Cheshire, UK) [26]. It was almost simultaneously trade-
marked by BioVisioN, a Hannover based biotech company (see
below). Afterwards, the two executive founders scientiﬁcally
introduced it in February 2000 at an ABRF conference orga-
nized by Aebersold (Bellevue, Washington, USA) [27]. The term
ﬁrst appeared in several full scientiﬁc papers in 2001 [28–33].
Peptidomics is deﬁned as the comprehensive characteri-
zation of peptides present in a biological sample. Since its
ﬁrst use, the term peptidomics (or peptidomic) has been used
in over 400 publications listed on PubMed (Fig. 1). Including
the term “peptidome” together with peptidomic(s), PubMed
searches reveal over 600 publications (Fig. 1). Peptidomics is
a speciﬁc subdiscipline of proteomics, the characterization of
proteins in a biological sample, which has considerably more
publications listed in PubMed (Fig. 1). A few years after intro-
duction, already a few special issues were dedicated to peptide
analysis and peptidomics (e.g. [34,35]). Moreover, several books
have been published speciﬁcally targeting this new research
area (e.g. [36,37]).
Although peptidomics and proteomics are related, there
are fundamental differences in the conceptual as well as
subsequent analytical strategies in both these ﬁelds. The
ﬁrst comprehensive proteomics technology used on a world-
wide, large scale basis has been 2-D polyacrylamide gel
electrophoresis [38]. The beauty of this technology was that
proteins were fractionated by isoelectric point on one dimen-
sion and apparent molecular weight on a second dimension,
thereby allowing for the detection of thousands of proteins
on a single gel. Post-translational modiﬁcations that altered
the isoelectric point or electrophoretic mobility could be
detected. However, further work was required to sequence
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Fig. 1 – Usage of proteomic(s) and peptidomic(s) in the
scientiﬁc literature. PubMed
(http://www.ncbi.nlm.nih.gov/pubmed) was searched with
various terms in all ﬁelds (title, abstract, key words, etc.)
and the number of citations per year plotted. Top panel:
comparison of proteomic/s (circles) and proteome
(triangles). For proteomic/s, the database was searched
with the terms “proteomics” OR “proteomic”. For
proteome, PubMed was searched with the terms
“proteomics” OR “proteomic” OR “proteome” and the
additional number of citations per year from the inclusion
of the term proteome was calculated. For 2013, the data
reﬂects the estimated count of publications for this year,
and was determined from the publications over the ﬁrst 9
months of 2013 multiplied by 1.33. Bottom panel: similar
analysis was performed for the terms “peptidomic” OR
“peptidomics” (circles) and “peptidome” (triangles), and
2013 was estimated as described above. Note the 100-fold
difference in the scale of the y-axis between the top and
bottom panels.
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frequency of Lys and Arg in the proteome) with a charge state
of 2 (more if His residues are present). Nearly all of the tryp-ach separated protein spot, which was one of the main limi-
ations of the 2-D gel technology.
Driven by the availability of protein- and later genome
atabases in combination with more  powerful mass spectro-
eters the proteomics workﬂows almost universally adopted
 “bottom-up” approach that digests the proteins with trypsin
r another enzyme to generate peptides that are analyzed on
C–MS/MS. In this approach, the precise forms of the endoge-
ous proteins are deliberately destroyed, and this information
s therefore lost, but the advantage is the rapid identiﬁcation of
 large number of proteins present in the biological sample. In
ontrast, and very much alike classical proteomics using 2-D
el technology, peptidomics mostly aims to elucidate the exact
orm of each peptide detected in the sample, which reﬂects
roteolytic cleavages, other post-translational modiﬁcations,
nd the co-existence of different versions of peptides derived
rom the same gene or precursor in a sample (Fig. 2). ( 2 0 1 4 ) 171–182 173
Because peptidomics does not require enzymatic diges-
tion of the sample, at ﬁrst glance it may be considered to
be easier than proteomics. However, there are several fac-
tors that make peptidomics more  difﬁcult that proteomics,
including sample preparation (discussed in the next section)
and data analysis. Endogenous peptides range considerably
in size and properties, and MS/MS sequence determination
from 5+ to 10+ charge states is not a trivial task [39]. Further-
more,  without the constraints of sites for trypsin (or another
protease) in the data analysis, data base searches become a
real challenge, and one may estimate that the false positive
rate is 100 times higher for peptidomics than for proteomics.
Another aspect is the trend that for most proteomic studies,
proteins identiﬁed with only a single tryptic (or other pro-
teolytic) fragment are considered too questionable and are
therefore rejected [40]. In some cases, the threshold is set
even higher and up to ﬁve peptides are required for a pos-
itive identiﬁcation. In contrast, peptidomic studies rely on
single identiﬁcations because each peptide is present in the
peptidome only once (although multiple peptides are often
produced from each prohormone). Furthermore, peptidomic
analyses, need to allow for a range of cleavage sites and post-
translational modiﬁcations. Thus, a “top-down” approach is
performed in which it has been necessary to manually evalu-
ate the MS/MS spectra generated in peptidomic analyses and
verify that the assignments of peptides are accurate [28,39,41].
Hopefully, the ongoing technological improvement in mass
spectrometry and bioinformatics will ameliorate these difﬁ-
cult issues in peptidomics.
2.2.  Developing  analytical  technology
Peptide research during the last decades has been sub-
stantially driven by innovations in analytical chemistry. As
bioactive peptides occur in very low concentrations within
complex biological matrices, analytical methods have to be
very sensitive and rely on a speciﬁc sample preparation strat-
egy. Peptides contain secondary structure elements, but do
rarely form stable three-dimensional structures, and conse-
quently, their folding behavior is not too complicated and
mostly reversible. The development of a large variety of
media (e.g. reversed-phase or ion-exchange) for HPLC enabled
improved puriﬁcation of low-concentrated compounds from
complex matrices [31,42,43], which is still a critical step [44].
With the development of ESI-MS [45] and MALDI-MS [46]
as new technologies about 25 years ago, mass spectrometry
became the perfect tool for the detection of peptides. These
breakthroughs accomplished soft ionization of intact peptide
molecules and acceleration into a vacuum without substantial
fragmentation. Increasing resolution, sensitivity and speed
allowed for measurements in complex mixtures. Furthermore,
identiﬁcation was made possible by MS/MS  experiments [47].
To facilitate the mass spectrometric analysis of proteins,
they are usually digested into peptides. Trypsin became the
enzyme of choice to cleave proteins because it typically gen-
erates peptides of about 10 residues in length (based on thetic fragments contain a basic residue on the C-terminus as
well as a second positive charge on the N-terminus, ensuring
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Fig. 2 – General methods of peptidomics and proteomics. The process of peptidomics and proteomics can be divided into
ﬁve main steps. Highly relevant methods in peptidomics are given for each step and compared to typical methods used in
proteomics. An asterisk indicates methods unique to peptidomics and a circle those which are also used routinely in
proteomics. Two main differences are crucial in the identiﬁcation process of the molecules and are pointed out in bold.
Whereas peptides have to be puriﬁed while any proteolytic activity is suspended, proteins are usually cut into tryptic
fragments before further analyses. The identiﬁcation in proteomics relies on automated analyses of mass spectrometric
data using several, but usually only a fraction of all possible tryptic fragments. In contrast, in peptidomics each peptide
identiﬁcation has to rely on MS/MS  data of a single peptide which has to be carefully interpreted manually. This includes all
potential modiﬁcations that shift masses and thus impede identiﬁcations. If quantiﬁcation of hits is needed after discovery,
both technologies mainly rely on isotopic labeling and subsequent mass spectrometric quantiﬁcation of shifted signals,
although the type of labels might differ. 1Isobaric isotopic tags are isotopically labeled chemicals that covalently bind to
peptides or proteins to improve mass spectrometric quantiﬁcation (e.g. iTRAQ, TMT  [89] or TMAB [91]). 2Alternatively,
eled peptides might be synthesized directly with isotopically lab
good signal intensities of the fragment ions and allowing for
relatively straightforward sequencing. Although enzymatic
digestion leads to more  sample complexity, the improved
quality of the data more  than compensates for this. The
measurement of enzymatically cleaved peptide ﬁngerprints
became the main application of MALDI-MS.
ESI-MS was substantially improved in sensitivity by the
introduction of nano-electrospray and hence used to derive
sequence information of low amounts of trypsinized proteins
[48]. A substantial increase in sensitivity compared with nor-
mal  electrospray, extended acquisition time and a preferred
formation of higher charge states resulted in more  compre-
hensive MS/MS  fragmentation data. A reconstruction of the
protein is achieved in the consequent analysis now commonly
called “bottom-up” proteomics. An essential requirement was
the parallel development of sophisticated software tools and
biological databases to interpret the wealth of complex infor-
mation represented within protein-derived mass spectra. A lot
of bioinformatics research had been carried out that ﬁnally
yielded several robust MS/MS  identiﬁcation algorithms [49].
All these developments were mainly driven by the needs(e.g. deuterated) amino acids.
in the proteomics ﬁeld [50,51] as the number of researchers
becoming involved in that wide ﬁeld has always been much
larger than in peptidomics. Nonetheless, both areas remained
closely connected and shared experiences extensively.
2.3.  Adjustment  of  proteomics  techniques  to  peptides
Although most proteomic studies were performed via analysis
of tryptic peptides, it was not straightforward to use proteomic
techniques for studies on endogenous peptides. First, the
endogenous peptides range in size from 2 to over 100 amino
acids (the distinction between a protein and peptide is some-
what arbitrary; if a neuropeptide precursor protein is cleaved
into fragments, those fragments are considered peptides). Sec-
ond, the charge state of the endogenous peptides is not nearly
as uniform as for tryptic peptides. Some endogenous peptides
have no positive charge due to a blocked N-terminus (acety-
lation or pyroglutamylation) and the absence of Lys, Arg, or
His residues; these peptides cannot be detected in positive
ion mode. In contrast, other endogenous peptides have charge
states of 7 (e.g. beta-endorphin 1–31, gamma-lipotropin, and
 c s 3
o
p
o
p
c
e
o
c
a
s
d
s
c
a
o
a
p
c
t
l
t
p
c
p
b
m
r
t
i
r
a
a
2
T
t
i
o
s
c
t
t
i
p
a
p
w
e
a
o
i
p
c
[
s
t
me u  p a o p e n p r o t e o m i
thers). These variations in peptide size and charge state com-
licate the analysis of endogenous peptides. Because a goal
f most peptidomic studies is to identify all of the abundant
eptides in a sample, even those peptides with many  positive
harges or large sizes are of interest. Therefore, it was nec-
ssary to adjust the basic techniques used for proteomics in
rder to identify large numbers of endogenous peptides.
Many  developments in proteomics directly fostered the
apabilities in peptide research. In order to analyze peptides of
 whole organism or a subsystem as comprehensively as pos-
ible, puriﬁcation/fractionation by liquid chromatography was
eveloped. The combination of HPLC and mass spectrometry
et a new standard in peptide research. Their high-throughput
apabilities are for example reﬂected in the steady disappear-
nce of tedious earlier techniques such as Edman sequencing
r amino acid analysis. The high sensitivity of MALDI-MS
nd its tolerance against interference by salts and other com-
onents allowed for the detection of native peptides from
omplex biological mixtures with reduced sample prepara-
ion efforts. One example was the comprehensive analysis of a
arge natural peptide library from blood ﬁltrate after ultraﬁltra-
ion with a molecular cut-off at about 20 kDa [7] obtained from
atients with end-stage renal disease. MALDI-MS was used to
atalog all fractions and also as an alternative assay system for
uriﬁcations of native human blood peptides [52]. This had
een accomplished also by comprehensive screening using
icrobore LC–MS [43], a combination that had been the fore-
unner for capillary LC–MS [53,54]. Soon, it became possible
o analyze native peptides in a variety of biological samples,
ncluding body ﬂuids [30,43,53], cell cultures [55], tissue prepa-
ations [56,57] and, single cells [58]. Another area with early
ctivities has been the research in insect [28,29,59–61] and
mphibian [56,62] peptidomics (see also [37]).
.4.  Comprehensive  peptidomics
he aim of comprehensive peptidomics is to detect and iden-
ify all endogenous peptides in the biological system under
nvestigation. The many  years of experience in puriﬁcation
f peptide hormones helped to come up with several robust
ample preparation procedures. The new challenge was the
omprehensive analysis of the entire peptide content. Thus
he unbiased identiﬁcation of biologically interesting pep-
ides became possible without the aid of a given bioassay or
mmunoassay. At that time, MALDI-MS after careful sample
reparation already exhibited substantial performance in rel-
tive quantiﬁcation. First impressive results were shown for
ituitary peptides from rat neurointermediate lobes [63] as
ell as fruitﬂy hemolymph [64]. Based on their own experi-
nces and further inspired by these experiments some of us
pplied for a general patent application claiming the detection
f the status of an organism by differential measurement of
ts peptide content [65]. This led to the formation of the com-
any BioVisioN. There, proof of concepts could be shown for a
linically relevant polymorphism of a blood coagulation factor
66] and in mouse models of diabetes [67].Simultaneously, approaches relying on nanoscale LC–MS
tarted dominating the ﬁeld of proteomics and also pep-
idomics [59]. Even though these needed some optimization,
ore and more  robust sample preparation procedures, ( 2 0 1 4 ) 171–182 175
hardware and reproducible data interpretation have become
standard [44,53,60,68,69]. The massive parallel sequencing
approach used for identiﬁcation of the genome was also
applied to proteomics and peptidomics. With the techno-
logical developments, additional strategies with well-deﬁned
biological hypotheses aiming for comparisons of differentially
expressed proteins became favored [50]. Because of the direct
applicability of liquid chromatography for peptides, several
quantiﬁcations could be developed quite early. The ﬁrst meth-
ods still relied on classical standard calibration curves for
single analytes using ofﬂine combination of LC and MALDI-MS
[70]. Proteomics switched more  and more  to online capillary
LC-ESI-MS with automated data interpretation [53,54]. Further
quantitative methods using mass spectrometry in combina-
tion with chemical tagging for proteomics quantiﬁcations had
been under development [71]; this is commented on in a later
section.
As a cornerstone of comprehensive peptidomics strate-
gies, the identiﬁcation of a peptide of interest is concerned
with the exact form of a single target peptide detected in
the sample. Essential experiments were already performed
in 1990 [72]. However, the mass resolution available with
the triple-quadrupole instrumentation used at that time was
not sufﬁcient to determine all underlying charge states.
Furthermore, the lack of appropriate database search routi-
nes resulted in tedious identiﬁcation processes of unknown
peptides with insufﬁcient success rates. The concerted devel-
opment of mass spectrometric hardware and software made
these identiﬁcation processes far more  efﬁcient and they
had been called top-down approach afterwards [73]. Better
data quality combined with automated software tools for
database comparison and increasing publicly available pro-
tein sequence data made straightforward identiﬁcations from
peptidomic MS/MS fragmentation data possible [28,39,54]. The
complex data could be automatically reduced to the essential
information for sequence identiﬁcation. However, the lack of
posttranslational modiﬁcations in appropriate database for-
mat  and technical and biological complexity still need careful
evaluation of MS/MS data [74,75] by experienced users to gen-
erate data of high quality and proper ﬁnal interpretations.
This is especially true, if no appropriate database entries exist.
Consequently, so-called de-novo strategies have to be applied
[76–79]. Subsequent analysis with the help of further appropri-
ate bioinformatic tools [75,80] allow for veriﬁcation and better
understanding of the biological context.
2.5.  Adjustment  of  traditional  techniques  used  for
peptide  research
In addition to the adjustments described above, there were
some necessary changes between the older studies on pep-
tides and newer peptidomics approaches. Many of the studies
on neuropeptides from the 20th century started with fresh
brain tissue that was dissected into regions and extracted with
hot acid, which served to both solubilize the peptides and inac-
tivate any proteases that would degrade the peptides. When
similar techniques were used to process tissue for peptidomics
studies, very few neuropeptides could be detected by LC–MS.
Instead, the vast majority of the peptides detected were iden-
tiﬁed as protein degradation fragments. This changed when
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rodents were sacriﬁced by focused microwave irradiation to
rapidly heat their brains to >90 ◦C; most of the protein degra-
dation fragments were eliminated, allowing for the detection
of neuropeptides that were otherwise overwhelmed by the
stronger signals from the numerous protein degradation frag-
ments [81]. In addition, the signals from the neuropeptides
were slightly higher when the brains were microwave irra-
diated, compared to unheated brain tissue [82], consistent
with previous studies that examined peptides using non-
peptidomic techniques [83–85]. It did not matter if the animals
were sacriﬁced by microwave irradiation (using specialized
equipment that sends focused rays to the brain, heating it to
>90 ◦C within seconds) or by decapitation followed by imme-
diate microwave irradiation of the head—both techniques
led to greatly improved detection of peptides [81,82]. Addi-
tional studies found that rapid removal of the brain and
immediate heating using other devices could also prevent the
postmortem degradation of proteins and loss of neuropeptides
[86].
The other major problem with the extraction techniques
used for many  of the older studies on peptides was due to
exposure of the tissue to hot acid. Even relatively mild acids
(10 mM HCl) and moderate temperatures (80 ◦C) for short times
(15 min) can lead to cleavages at sensitive sites; primarily Asp-
Pro bonds, but also other bonds near Asp [68]. In previous
studies that detected peptides using radioimmunoassays, it
did not matter if a small fraction of the peptides or cellu-
lar proteins was degraded during the extraction. However,
with ultrasensitive mass spectrometers, shorter fragments of
abundant peptides were detectable. As outlined above, any
degradation of peptides during the extraction procedure leads
to artifacts. Avoiding the use of hot acid eliminates this prob-
lem.
2.6.  Development  of  quantitative  peptidomics
As with proteomics, many  of the important research ques-
tions in the ﬁeld of peptidomics involved studies comparing
peptides levels in two or more  biological samples. Some of the
isotopic labels developed for quantitative proteomics (such as
reagents, which react with the thiol group on Cys [71]) were
appropriate for many  peptide hormones and especially for
tryptic fragments of proteins even after chemical reduction.
However, comprehensive peptidomic studies were not suc-
cessful because of the absence of Cys residues in the vast
majority of endogenous peptides. Complementary, reagents
that label free amine groups were found optimal for pep-
tidomics because nearly all endogenous peptides have either a
free N-terminus or a Lys residue. A number of different isotopic
tags were tested, including acetic anhydride, succinic anhy-
dride, and others [87,88]. While these reagents are relatively
inexpensive and easy to use, they suffer from various prob-
lems. A major issue is that the free amine is converted into
a neutral residue (acetyl) or negative residue (succinyl), and
if the peptide does not contain an Arg or His residue, it will
not be positively charged and therefore not detected in MS
when run in positive ion mode. Another issue is that peptides
labeled with the deuterated form of the tag tend to elute from
reverse phase chromatography columns slightly earlier than
the peptide labeled with the hydrogen form of the tag. This 3 ( 2 0 1 4 ) 171–182
elution difference made quantiﬁcation less accurate. Finally,
these labels only came in heavy and light forms, allowing for
two-way comparisons of samples.
Several of the isotopic tags developed initially for pro-
teomics research are very useful for peptidomics research.
The reagents used for iTRAQ (isobaric tags for relative and
absolute quantiﬁcation) as well as other isobaric tag reagents,
including tandem mass tags (TMT), can be easily adapted to
peptidomics studies [89]. Another set of reagents for quanti-
tative peptidomics is the trimethylamino-butyryl (TMAB) tags.
Originally developed for proteomics in a heavy and light form
[90], the TMAB tags can be produced in 5 different isotopic
forms [91]. Importantly, because the TMAB reagent contains
a quaternary amine, peptides labeled with the different iso-
topic forms of TMAB co-elute from reverse phase columns
and maintain the charge of the peptide [87]. For these reasons,
TMAB labels are ideal for quantitative peptidomics.
3.  Applications  of  peptidomics
3.1.  General  uses  of  peptidomics
There are two major directions that peptidomics has been
used for. One is the discovery of new molecules, such as the
family of neuropeptides derived from the precursor proSAAS
[20,21], and numerous peptides from Aplysia, crab, Drosophila,
and other organisms [54,69,78,92–97]. The knowledge of pep-
tides that exist within cells and tissues has opened up
new insight in function of biological systems, leading to
the hypothesis that several endogenous peptides may be
involved in the control of protein–protein interactions [98,99].
The other major use of peptidomics is the measurement of
levels of peptides, either absolute or relative, using quantita-
tive techniques. Examples include studies examining changes
in neuropeptide or pancreatic hormone processing in mice
lacking peptide processing enzymes [67,100–104], or biolog-
ical systems upon exposure to drugs or other treatments
[60,79,105–110]. The discovery of peptide biomarkers includes
a relative quantiﬁcation of the peptide analytes in different
biological sources focusing on those with signiﬁcant changes
in concentration [30,53,55,66,111,112].
3.2.  Novel  functional  peptides  by  chemical
determination
Biologically active peptides often contain speciﬁc posttrans-
lational modiﬁcations. In small peptides containing disulﬁde
bridges, the cysteine content (in %) is usually higher than in
proteins in general [113] and is often linked with biological
activity. Therefore, an assay using chemical modiﬁcation and
subsequent liquid chromatography was developed to detect
cysteine-rich peptides in tissue extracts [113]. In a ﬁrst attempt
using peptidomics technology to screen biological ﬂuids for
such peptides, labeled cysteines were selectively detected by
molecular mass shifts of 116 Da in differential MALDI-MS [114],
corresponding to a pair of cysteines. With the help of this
approach it was possible to identify several new truncated
variants of a known beta-defensin in blood ﬁltrate as well
as in urine [115]. Moreover, a new peptide with four disulﬁde
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ridges within only 25 amino acids was discovered and named
epcidin, reﬂecting its production in liver and its antibiotic
roperties [116]. After years of additional research, hepcidin is
ow known to play a major role in iron metabolism [117]. Hep-
idin is a promising biomarker for iron disorders, and assays
o quantify hepcidin concentration in human body ﬂuids have
ecently been developed [118].
As already mentioned, Mutt and Tatemoto were ﬁrst
ith a chemical determination of a C-terminal amide group
n peptide hormones instead of using a bioassay [4]. In a
ecent study, nineteen C-terminally amidated peptides were
dentiﬁed from thyroid carcinoma cells using peptidomic tech-
ology, including novel bioactive peptides derived from the
eurosecretory protein named VGF [119]. Recently published
pproaches elegantly combined peptidomic know-how with
he knowledge about proteolytic processing toward bioactive
eptides. One group followed the same target as Mutt and
atemoto by combining an enzymatically catalyzed cleavage
f a C-terminal glycine speciﬁcally resulting in a truncated
nd amidated C-terminus with mass spectrometric detec-
ion [120]. Growth of cultured cells in the presence of an
nhibitor ensured the coexistence of both -amidated pep-
ides and their precursors with a mass difference of 58 Da. A
ifferential display by liquid chromatography and mass spec-
rometry allowed for easy detection as the peptides exhibit
imilar RP-HPLC properties and MS/MS  fragmentation pat-
erns. In a mouse pituitary tumor cell line, known to express
igh levels of this speciﬁc enzyme, thirteen -amidated pep-
ides could thus be identiﬁed by MS/MS.  Similar approaches
o reveal unknown pathways and preferred processing sites
f peptidases were published earlier in combination with
ther proteolytic enzymes. This has been demonstrated for
xample in screening a neuropeptidome to characterize the
ubstrate speciﬁcity of an extracellular matrix-bound metal-
ocarboxypeptidase [121] or the comprehensive peptidomics
nalysis of dipeptidyl-peptidase 4 activity in rat plasma [108]
r in kidneys from mice lacking this enzyme [109].
.3.  Peptidomic  biomarker  discovery  as  a  business
 biomarker by deﬁnition is a characteristic that is objectively
easured and evaluated as an indicator of normal biologic
rocesses, pathogenic processes or pharmacologic responses
o a therapeutic intervention [122]. The aim of many  pro-
eomic and peptidomic studies is the search for molecular
nalytes which correlate with disease states [30,112,123,124].
here are many  prominent examples for peptide biomarkers.
hese include the C-peptide of proinsulin in diabetes [125],
atriuretic peptides in heart diseases [126] or amyloid peptides
orrelated with Alzheimers [127].
The company BioVisioN was dedicated to peptidomics
echnology and located in Hannover (Germany), with concepts
riginally developed at the Lower Saxony Institute of Peptide
esearch [65]. BioVisioN started in 1997 as “The Peptidomics
ompany” and grew quickly to more  than 50 people in staff
orking with many  different partners for about ten years
n biomarker projects [15,30,36,66,67,80,128], several of them
ogether with industry, e.g. [112]. It went through the down-
izing cycles many  proteomics companies also experienced,
nd now proceeds as the small bioanalytical service company ( 2 0 1 4 ) 171–182 177
PXBioVisioN [107]. Other pioneers like Geneprot (Switzerland)
had substantial ﬁnancial backing and focused on industry
collaborations for both biomarker and target ﬁnding, but
essentially had the same fate as BioVisioN. Another rele-
vant company, also from Hannover, Germany, is Mosaiques
Diagnostics. They started in 2002 applying capillary elec-
trophoresis coupled to mass spectrometry as a high resolution
separation technology, especially focusing on the analysis of
urine as a peptide source [129] to establish diagnostics in a
variety of human disorders [124]. Currently, Proteome Sciences
(United Kingdom) is another one of the remaining biotech
companies involved in quantitative MS (having developed
Tandem Mass Tags which were licensed to Thermo Scientiﬁc).
Proteome Sciences has initially performed large scale discov-
ery studies on 2-D gels but has recently begun to work with
an LC-Orbitrap-MS based peptidomics workﬂow using isobaric
tagging.
With the introduction of a chip-based MALDI mass
spectrometry system (SELDI: surface enhanced laser desorp-
tion/ionization) by Ciphergen (USA), readily applicable in a
clinical setting, academic peptidomic biomarker projects were
fostered for a while [130]. However, results became question-
able as technical issues started to compromise the intrinsic
value of their peptidomics claims. As in many  proteomics
projects, main difﬁculties were in reproducibility [131] and,
typical for peptidomics, lack of identiﬁcations [132] as both
was difﬁcult to achieve with the early systems.
Peptidomics-based efforts toward biomarker discovery
have delivered hundreds of promising candidates, although
practically no valid biomarkers have emerged from any of
these studies. This is a general criticism of most omics tech-
nologies, and is most likely the result of a combination of
an underestimation of the actual complexity in biological
samples, insufﬁcient sample size and quality, inappropri-
ate study design, a lack of detail of clinical data in human
disease-studies, and problems with reproducibility of data
and errors due to degree of stringency in statistical analysis
[40,44,128,131,133,134]. Another critical issue is the preferred
use of plasma for peptidomic analyses of blood. Peptides
derived from ﬁbrinogen and other abundant proteins in serum
samples predominate in the LC/MS analysis and overwhelm
the weaker signals of biologically active peptides [15]. Addi-
tionally, studies have to be further analyzed using appropriate
bioinformatics tools [75,80] and subsequent validation proce-
dures quantifying the discovered hits by immunoassays or
mass spectrometry [135,136]. The combination of all these
skills is still a challenge.
4.  Peptidomics:  quo  vadis?
4.1.  New  concepts  based  on  peptidomics  technologies
(MS)
Imaging mass spectrometry is a new technology that allows
for the spatial detection of analytes in tissue sections by
MALDI-MS [137]. Most of these analytes are still unidentiﬁed.
However, as this detection works best in a range from about 1
to 10 kDa, many  endogenous peptides as well as protein frag-
ments will be involved and several were already identiﬁed
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[138,139]. MALDI-MS is an excellent screening tool, but most
often does not allow a direct subsequent identiﬁcation of pep-
tides of interest. However, peptidomics technologies had to
solve the same issue [28,39] and their adjusted application
allows for signiﬁcant improvements in the understanding of
interesting signals and the biological relevance of underlying
peptides [139].
The close scrutiny of data from the human genome project
reveals that not all sequence information is well understood.
Several short open reading frames (sORFs) coding for peptides
with less than 50 amino acids have recently been deciphered
by a peptidomics strategy [140]. These ﬁndings provide evi-
dence that coding sORFs constitute a signiﬁcant human gene
class representing a new family of biologically relevant pep-
tides.
Another new approach is an MS-based genome mining
platform to discover novel ribosomal as well as nonriboso-
mal  peptides. It enables screening of peptide chemotypes from
multiple organisms whereas identiﬁcation is performed by de-
novo MS/MS  sequencing [141].
5.  Concluding  remarks
Endogenous, native peptides cover a multitude of biological
functions without which life would not exist. A comprehen-
sive research strategy and speciﬁc technologies to address
these biomolecules are therefore required. Peptidomics is the
research ﬁeld which has established itself in order to address
this challenge and to deliver upon the promise peptides have
for research and health. In the ∼15 years since the beginning of
the ﬁeld of peptidomics, there has been a continuous growth
in application of peptidomics to basic and clinical research.
The techniques have improved dramatically, and new tech-
niques (like imaging mass spectrometry) have been developed.
Early users had to be experts in the sophisticated combina-
tion of analytical technologies which are similar, but not the
same as in the more  widespread applications of proteomics.
The ﬁeld has now become available to researchers following
interesting biological questions without being technological
experts. Thus the number of publications has risen steadily
over recent years. As further improvements in mass spectro-
meters are made, it is expected that the ﬁeld of peptidomics
will continue to advance signiﬁcantly, and that more  and more
proteomics as well as clinical research groups will add pep-
tidomics strategies and workﬂows to their diverse portfolios
of research programs. Improved diagnostics, as well as novel
therapeutic approaches using peptides can be expected in the
not-too-distant future.
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